Promising new data show nivolumab plus ipilimumab combination achieves unprecedented survival benefit in skin cancer

Bristol-Myers Squibb has announced the first overall survival results from CheckMate -069, a Phase II trial evaluating the investigational combination of nivolumab and ipilimumab vs.